TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05027971

Intervention type: DEVICE
Intervention: Flexiva Pulse High Power Single-Use Laser Fibers
Description: Flexiva Pulse High Power Single-Use Laser Fibers are intended to be used as a device that transmits Ho:YAG laser energy from cleared laser consoles to urological anatomy.

Intervention type: DEVICE
Intervention: Flexiva Pulse High Power Single-Use Laser Fibers
Description: Flexiva Pulse High Power Single-Use Laser Fibers are intended to be used as a device that transmits Ho:YAG laser energy from cleared laser consoles to urological anatomy.
Study: NCT06576596

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: apnoeic Oxygenation
Description: One approach to preventing adverse respiratory events due to hypoxaemia during paediatric anaesthesia is the use of apnoeic oxygenation. The principle is to deliver oxygen to the airways of anaesthetised patients via a conventional nasal cannula. As less carbon dioxide is produced than oxygen is consumed during apnoea, the supply of oxygen to the upper airways leads to an 'inward diffusion' of oxygen, which may prolongs the time until desaturation and hypoxaemia occur.
Study: NCT06435299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis oil
Description: Patients in this arm will have to take Cannabis oil (50mg/mL) twice a day with the daily dose estimated during auto titration phase (from W0 to W2)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in this arm will have to take Placebo oil twice a day with the daily dose estimated during auto titration phase (from W0 to W2)
Study: NCT06032234

Intervention type: OTHER
Intervention: This is an observational study
Description: This is an observational study

Intervention type: OTHER
Intervention: This is an observational study
Description: This is an observational study
Study: NCT04872959

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HealthReveal
Description: In the Intervention arm, for each study visit, the site will receive a pre-visit assessment of GDMT accompanied by recommended adjustment(s) using information extracted weekly from the sites' EHR.~The recommended adjustment(s) will be conveyed using proprietary software from HealthReveal, with a suggested follow up plan. All reminders regarding dosing targets are based on the 2020 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment.~Additionally, during visits at baseline, 3 months, and 6 months, the KCCQ-23 will be completed.~In the Usual Care arm, during visits at baseline, 3 months, and 6 months, the KCCQ-23 will be completed.
Study: NCT04981457

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol and iso sorbide mononitrates
Description: drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol and iso sorbide mononitrates
Description: drug
Study: NCT05289557

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bonjesta
Description: Extended-release tablets contain 20 mg of doxylamine succinate and 20 mg of pyridoxine hydrochloride. Minimum 1 tablet at bedtime. Up to two pills daily (one tablet in the morning and one tablet at bedtime). The treatment duration is 15 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pills with no active ingredients. Minimum 1 tablet at bedtime. Up to two pills daily (one tablet in the morning and one tablet at bedtime). The treatment duration is 15 days.
Study: NCT05396287

Intervention type: DEVICE
Intervention: MRI
Description: Participants will undergo an MRI scan while participating in two breathing tests (hypercapnia and hypoxia) to measure brain blood flow.

Intervention type: DEVICE
Intervention: MRI
Description: Participants will undergo an MRI scan while participating in two breathing tests (hypercapnia and hypoxia) to measure brain blood flow.
Study: NCT05406726

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: palmitoylethanolamide
Description: palmitoylethanolamide is an lipid based endocannabinoid naturally made by the body and is present in several common foods such as eggs

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a capsule filled only with maltodextrin will be used as a placebo
Study: NCT04960618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Participants will receive gemcitabine 1000 mg/m2 on days 1 and 8 on 21-days cycles for up to 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg will be introduced with cycle 2 and will be given on day 1 of each 21-day cycle for up to 35 cycles
Study: NCT06522867

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intraocular pressure measure
Description: The intraocular pressure of the subjects using either the Goldmann applanation tonometer, Icare or Accupen. The order of the measure is randomized.
Study: NCT04887285

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Subjects in the virtual reality group will be offered a variety of immersive environments to choose from (mountains, beach, rainforest and temperate forest) in addition to local anesthetic.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous sedation
Description: Sedation will be administered using low-dose midazolam and/ or fentanyl. We will use a wide range of dosing (1-5 mg for midazolam, up to 150 mcg for fentanyl) to maximize generalizability and account for widespread variability in clinical circumstances, medical practice and patient response (personalized medicine). Sedation will be titrated to effect by a board-certified or eligible anesthesiologist so that patients remain responsive to verbal stimuli.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: Patients will receive superficial local anesthetic with 1% lidocaine. Local anesthetic will be administered by the physician performing the procedure titrated to patient comfort.
Study: NCT04893798

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Sayana Press
Description: Sayana Press is a drug-device combination and is considered a medical product in the EU.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Sayana Press
Description: Sayana Press is a drug-device combination and is considered a medical product in the EU.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Sayana Press
Description: Sayana Press is a drug-device combination and is considered a medical product in the EU.
Study: NCT04903002

Intervention type: DRUG
Group type: OTHER
Intervention: 24-IU oxytocin
Description: Patients will self-administer a 2-week course of 24-IU intranasal oxytocin \[4-IU per puff (12-IU delivered to each nostril); Syntocinon, Novartis, Switzerland\], twice per day (once in the morning and once in the evening).

Intervention type: DRUG
Group type: OTHER
Intervention: 24-IU oxytocin
Description: Patients will self-administer a 2-week course of 24-IU intranasal oxytocin \[4-IU per puff (12-IU delivered to each nostril); Syntocinon, Novartis, Switzerland\], twice per day (once in the morning and once in the evening).
Study: NCT05771792

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ECCENTRIC EXERCISE
Description: Eccentric Exercise training group will perform 8 weeks of protocol with a total 24 sessions for 45 minutes (3 session per week). During each 45 minutes training session, subjects will complete the warmup for 10 minutes, Eccentric Exercise training for 25 minutes and cool down 10minutes. All players will perform each repetition in a slow, controlled manner, 10 repetition and 3 sets in first 4 week and 15 repetition and 3 sets in last 4 weeks of all exercises for 45 minutes. Eccentric exercise training protocol is as follow: Prone Hamstring Curl, Seated TheraBand Hamstring Curl, Exercise Ball (or glider) Bridge with Curl, Stiff-Legged Deadlift, Single Leg Deadlift, Nordic Hamstring Curl.
Study: NCT04903002

Intervention type: DRUG
Group type: OTHER
Intervention: 48-IU oxytocin
Description: Patients will self-administer a 2-week course of 48-IU intranasal oxytocin \[4-IU per puff (24-IU delivered to each nostril); Syntocinon, Novartis, Switzerland\], twice per day (once in the morning and once in the evening).

Intervention type: DRUG
Group type: OTHER
Intervention: 48-IU oxytocin
Description: Patients will self-administer a 2-week course of 48-IU intranasal oxytocin \[4-IU per puff (24-IU delivered to each nostril); Syntocinon, Novartis, Switzerland\], twice per day (once in the morning and once in the evening).

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Patients will receive an intranasal placebo containing the same ingredients as the oxytocin nasal spray with the exception of active oxytocin. Administration schedule and procedure will be identical to that described in 24-IU oxytocin.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Patients will receive an intranasal placebo containing the same ingredients as the oxytocin nasal spray with the exception of active oxytocin. Administration schedule and procedure will be identical to that described in 24-IU oxytocin.
Study: NCT04269070

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standing condition
Description: Participants will be asked to stand an additional 6 minutes per hour above their median standing time from the observed time in the usual behavior condition.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standing condition
Description: Participants will be asked to stand an additional 6 minutes per hour above their median standing time from the observed time in the usual behavior condition.
Study: NCT05771792

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CONVENTIONAL EXERCISES PROGRAM
Description: The participant of the Control Group will perform 8 weeks of protocol with a total 24 sessions for 45 minutes (3 session per week). During each 45 minutes training session, subjects will complete the warmup for 10 minutes, conventional training for 25 minutes and cool down 10minutes. All players will perform each repetition in a slow, controlled manner, 10 repetition and 3 sets in first 4 week and 15 repetition and 3 sets in last 4 weeks of all exercises for 45 minutes. The exercise will be as follow: Side Lunges, Split Squats, Calf Raises.
Study: NCT05873673

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coenzyme Q10
Description: cystic jaw defect filled with coenzyme Q10 gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: cystic jaw defect filled with placebo gel
Study: NCT05298306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAT8881
Description: In Part A, LAT8881 will be given as a single intravenous infusion at doses of 0.8, 1.2 and 1.8 mg/kg.~In Part B, a single intravenous infusion of LAT8881 will be given, the dose to be determined by the results in Part A

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo'given as a single intravenous infusion at all dose levels
Study: NCT06323707

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Eight sessions of moderate intensity aerobic exercise using recumbent bike within the cancer institution.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management e-module
Description: Eight 15 minute self-management e-modules related to exercise and physical activity for cancer survivors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management e-module
Description: Eight 15 minute self-management e-modules related to exercise and physical activity for cancer survivors.
Study: NCT04964024

Intervention type: DIAGNOSTIC_TEST
Intervention: SARS-CoV-2 antibodies
Description: Analysis of the results of the serological response to COVID-19 and/or Vaccine

Intervention type: DIAGNOSTIC_TEST
Intervention: SARS-CoV-2 antibodies
Description: Analysis of the results of the serological response to COVID-19 and/or Vaccine
Study: NCT06259955

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: In the hybrid education process, the group that received their first year education online realized their first face-to-face clinical practice this year. In the fall semester, internal medicine nursing course and practice, and in the spring semester, surgical diseases nursing course and practice. These two practice areas, which have a high tendency to make medical errors, require clinical decision-making skills and increase stress levels, constitute the beginning of clinical practice. Studies show that the most stressful period for students is the second year of their education (Alzayyat \& Al- Gamal, 2014; White, 2011; Coram, 2015). This is because their professional knowledge and skills are not yet fully developed and they are not sufficiently prepared to meet the demands for higher level knowledge and skills (Alzayyat \& Al- Gamal, 2014; Coram, 2015). Based on the results of these studies, our study group consisted of second-year students.
Study: NCT05116358

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phototherapy device
Description: The active phototherapy device will emit light

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Phototherapy device
Description: The active phototherapy device will emit light
Study: NCT04269070

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Light physical activity (LPA) condition
Description: Participants will be asked to perform 6 additional minutes per hour above their median LPA time from the observed time in the usual behavior condition.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Light physical activity (LPA) condition
Description: Participants will be asked to perform 6 additional minutes per hour above their median LPA time from the observed time in the usual behavior condition.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual behavior condition
Description: Participants will be asked to perform their normal work activities in their normal work environment for one week. There will be no modifications to their work environment or instructions given of what activities to partake in. This period will be used to understand their normal standing and LPA behaviors to determine the personalized changes to their standing and LPA behaviors in the other conditions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual behavior condition
Description: Participants will be asked to perform their normal work activities in their normal work environment for one week. There will be no modifications to their work environment or instructions given of what activities to partake in. This period will be used to understand their normal standing and LPA behaviors to determine the personalized changes to their standing and LPA behaviors in the other conditions.
Study: NCT05209399

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided injection
Description: All intraarticular hip injections will be performed under real-time ultrasound guidance using a GE LOGIQ P9 ultrasound machine with a C1-5-RS 1-5 MHz curvilinear transducer (GE Healthcare, Chicago, IL, USA). For the procedure, patients will be placed in a supine position. The curvilinear transducer and ultrasound machine will be used to visualize the anterior aspect of the hip joint in a sagittal oblique plane. Sterile technique will be used to perform the procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided injection
Description: All intraarticular hip injections will be performed under real-time ultrasound guidance using a GE LOGIQ P9 ultrasound machine with a C1-5-RS 1-5 MHz curvilinear transducer (GE Healthcare, Chicago, IL, USA). For the procedure, patients will be placed in a supine position. The curvilinear transducer and ultrasound machine will be used to visualize the anterior aspect of the hip joint in a sagittal oblique plane. Sterile technique will be used to perform the procedure.
Study: NCT05691907

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THE therapy
Description: THE therapy consisting of:~* Heating Pad~* Interferential Therapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THE therapy
Description: THE therapy consisting of:~* Heating Pad~* Interferential Therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Directional Preference Exercises
Description: Directional Preference Exercises consisting of Mckenzie's extension protocol

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Motor Control Exercises
Description: Motor Control Exercises consisting of External limb loading extension protocol
Study: NCT05702749

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Microsurgical resection of VS
Description: Microsurgical resection of VSs can be accomplished by three approaches including middle cranial fossa, retrosigmoid, and translabyrinthine. The surgical approach utilized is typically selected on the basis of tumor location and size, and patient age and hearing status.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microsurgical resection of VS
Description: Microsurgical resection of VSs can be accomplished by three approaches including middle cranial fossa, retrosigmoid, and translabyrinthine. The surgical approach utilized is typically selected on the basis of tumor location and size, and patient age and hearing status.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Stereotactic radiosurgery
Description: Radiation therapy will be delivered using single fraction stereotactic radiosurgery with Gamma knife technology, or linear accelerator following institutional standard of care.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic radiosurgery
Description: Radiation therapy will be delivered using single fraction stereotactic radiosurgery with Gamma knife technology, or linear accelerator following institutional standard of care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PREHAB
Description: A PREHAB visit will be done once weekly for 3 weeks to determine exercise regimen prior to surgery or radiotherapy. Therapy includes balance exercises (twice daily), gaze stabilization exercises (12-20 minutes daily), and habituation exercises (as applicable).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PREHAB
Description: A PREHAB visit will be done once weekly for 3 weeks to determine exercise regimen prior to surgery or radiotherapy. Therapy includes balance exercises (twice daily), gaze stabilization exercises (12-20 minutes daily), and habituation exercises (as applicable).
Study: NCT05418010

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tysabri Injectable Product
Description: Tysabri® is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis. Tysabri® 300mg concentrate for solution for infusion and matching placebo are collectively referred to as IMP when detailing to blinded trial procedures. Tysabri® 300mg will be colourless, clear to slightly opalescent solution.
Study: NCT04898114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Description: Nebulized magnesium sulfate (4 ml of 6.4% solution) every 15 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sildenafil Citrate
Description: Oral sildenafil citrate at an initial dose of 1 mg/kg, with incremental increases by 0.5 mg/kg every 6 hours till reaching a target dose of 2mg/kg every 6 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil Citrate
Description: Oral sildenafil citrate at an initial dose of 1 mg/kg, with incremental increases by 0.5 mg/kg every 6 hours till reaching a target dose of 2mg/kg every 6 hours.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline
Description: Nebulized isotonic saline (4 ml) every 15 minutes
Study: NCT05073731

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telerehabilitation-based Upper Extremity Training
Description: Telerehabilitation has been defined as the delivery of rehabilitation services through information and communication technologies.~Synchronized telerehabilitation provides the participant with advantages such as customized treatment, instant feedback, and a social environment such as face-to-face training.
Study: NCT05418010

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is colourless, clear to slightly opalescent liquid. The formulation of the is the same as that of commercial Tysabri® minus the active ingredient. Placebo is in the same containers/vials as Tysabri®.
Study: NCT06340880

Intervention type: OTHER
Intervention: Serratus anterior plane block
Description: ultrasound guided SAPB vs anatomical landmark guided SAPB
Study: NCT05073731

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation-based Upper Extremity Training
Description: Telerehabilitation has been defined as the delivery of rehabilitation services through information and communication technologies.~Synchronized telerehabilitation provides the participant with advantages such as customized treatment, instant feedback, and a social environment such as face-to-face training.
Study: NCT05783466

Intervention type: OTHER
Group type: OTHER
Intervention: Low-fat dairy products
Description: 3-month intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole-fat dairy products
Description: 3-month intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Milk polar lipid enriched whole-fat dairy products
Description: 3-month intervention
Study: NCT05019963

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NexJ Connected Wellness
Description: NexJ Connected Wellness is an electronic case management platform with a patient-facing smart phone application and a clinician-facing web dashboard.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Participants will receive a treatment plan as decided on with their clinician(s).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants will receive a treatment plan as decided on with their clinician(s).
Study: NCT06058351

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ABI-motion program
Description: The ABI-motion program strengthens the cooperation between outpatient rehabilitation professionals and community care providers.